Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 69 of 95, showing 5 Applications out of 471 total, starting on record 341, ending on 345

# Protocol No Study Title Investigator(s) & Site(s)

341.

ECCT/14/10/02  
    Acronymn: CRASH-3   Short Title: Clinical Randomisation of an Antifibrinolytic in Significant Head Injury   Full Title: Tranexamic acid for the treatment of significant traumatic brain injury: an international randomised, double blind placebo controlled trial   ISRCTN15088122   ClinicalTrials.gov ID: NCT01402882    
Principal Investigator(s)
1. Kiboi Githinji Julius
2. Dullo Michael
3. Lallet Tasneem Essaji
Site(s) in Kenya
1. Kenyatta National Hospital (Nairobi City county)
2. Kitui District Hospital (Kitui county)
3. The Nairobi Hospital (Nairobi City county)
 
View

342.

ECCT/21/06/01   ACTIV-2/A5401
    ACTIV-2/A5401 "Adaptive Platform Treatment Trial for Outpatients with COVID-19" (Adapt Out COVID)_   
Principal Investigator(s)
1. Charles Meja Kwobah
Site(s) in Kenya
1. Moi University Clinical Research Centre (Uasin Gishu county)
2. KEMRI Walter Reed Project (Kericho county)
 
View

343.

ECCT/21/05/03   Adapt Out COVID
    Adaptive Platform Treatment trial for Outpatients with COVID-19   
Principal Investigator(s)
1. Kawango Agot
Site(s) in Kenya
1. Kenya Impact and Research Development Organization (K-IRDO) (Kisumu county)
2. KEMRI WALTER REED (Kericho county)
3. MOI UNIVERSITY CLINICAL RESEARCH CENTRE (Uasin Gishu county)
4. Kenya Medical Research Institute (Kisumu county)
 
View

344.

ECCT/23/02/02   KARISMA
    An adaptive, randomized, active-controlled, open-label, sequential cohort, multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of intravenous cipargamin (KAE609) in adult and pediatric participants with severe Plasmodium falciparum malaria(KARISMA – KAE609’s Role in Severe Malaria)   
Principal Investigator(s)
1. Simon Kariuki
Site(s) in Kenya
KEMRI-CGHR,
 
View

345.

ECCT/23/07/04   PRAISE
    An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE)   
Principal Investigator(s)
1. Dr. Janet Oyieko
Site(s) in Kenya
1. Kondele Children\'s Hospital Center for Clinical Research (CCR), (Kisumu county)
2. Gertrude\'s Children Hospital (Nairobi City county)
3. KEMRI/CRDR Kemri Clinical Research Annex (Siaya county)
 
View